NTM & Bronchiectasis Conference for Healthcare Providers (Hybrid Event)

Wednesday
September 16 2026

Wednesday, September 16, 2026, 12:15 PM

Friday, September 18, 2026, 4:00 PM

Add to Calendar

National Jewish Health - Molly Blank Conference Center 1400 Jackson Street
Denver, Colorado 80206

Contact Information

First Name*

M.I.

Last Name*

Primary Phone Number*

Secondary Phone Number

Email*

Fax

Address*

Address line 2

City*

State*

Zip Code*

Country*

Employer Name*

Identification or Member Numbers for Certificate (NPI # required; RN license and state required; Pharmacist NABP ID required; AARC member #)

Date of Birth - Month and Day Only (MM/DD)

Degree (Examples: MD, DO, PA, NP, RN, etc.)*

Specialty*

Additional Information

How did you hear about this?*

Comments

Dietary Restrictions / Special Accommodations

Payment Information

Fees

Base Price: $0.000000000

In Person: MDs, DOs ($625.00)

In Person: Nurses and other Allied Health Professionals ($525.00)

Online: MDs, DOs ($500.00)

Online: NPs, PAs, RPhs, RNs and other Allied Health Professionals ($400.00)

Total: $0

Credit Card Information

Card Type*

Card Number*

Security Code*

Expiration Month*

Expiration Year*

Billing Information

Billing information is same as above

First Name*

Last Name*

Address*

Address line 2

City*

State*

Zip Code*

Country*

I hereby grant permission to National Jewish Health to share my information with the exhibitors and sponsors of this educational activity (name and credentials, institution/employer, city, state).

Purpose:

Nontuberculous mycobacteria (NTM) and bronchiectasis are complex, chronic respiratory conditions that pose significant diagnostic and therapeutic challenges for healthcare providers. NTM infections, caused by environmental mycobacteria, can lead to progressive lung damage, particularly in individuals with underlying lung diseases such as bronchiectasis. The interplay between these conditions contributes to worsening respiratory symptoms, frequent exacerbations, and reduced quality of life for affected patients. As the clinical burden of NTM and bronchiectasis becomes increasingly recognized, there is an urgent need to better understand the underlying mechanisms of inflammation, alongside efforts to improve early diagnosis and explore both current and emerging treatment options. We will have experts from across the country here to discuss this growing medical challenge. Come join us for an invaluable educational experience. The 2026 meeting will be offered as a hybrid, with the option to attend in-person or online. All attendees will receive access to the online video content and slides after the conference.

Provider Conference Objectives:

Recognize the incidence and distribution for both NTM disease and bronchiectasis
Identify the clinical features and unique manifestations of NTM disease
Identify the clinical features and underlying risk factors for development of bronchiectasis
Differentiate between the various types of NTM infections
Summarize the spectrum of bronchiectasis presentations and clinical evaluation
Describe current guidelines for the diagnosis and management of NTM disease and bronchiectasis
Apply the latest evidence to inform pharmacologic and non-pharmacologic management strategies for NTM disease and bronchiectasis

Who Should Attend:

Pulmonologists, infectious disease physicians, family and internal medicine physicians, physician assistants, advanced practice nurses, registered nurses, and other healthcare professionals such as radiologists who diagnose and treat patients with NTM and bronchiectasis.

VIEW CONFERENCE AGENDA

Add to Calendar

(Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window)

For Patients:

Please let your patients know about the NTM & Bronchiectasis: Patient & and Families Conference on Saturday, September 19, 2026.

National Jewish Health is the leading respiratory hospital in the nation. Founded in 1899 as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care.

View full list of Professional Education courses

VIEW CONFERENCE AGENDA

Topics:

Patient’s Perspective from the NTMir
Epidemiology of NTM
Environmental Sources of NTM
Host Susceptibility
Challenging Cases
Mycobacterial lab
Radiologic Evaluation of Pulmonary NTM Infections
Treatment of Slow Growing Mycobacteria
Treatment of Rapidly Growing Mycobacteria
Surgical Management
Emerging Therapies in NTM Pulmonary Disease
Drug Side Effects
Bronchiectasis
Cystic Fibrosis Related NTM Infections
Extrapulmonary NTM

The 2026 NTM & Bronchiectasis Conference for Healthcare Providers is a hybrid event. Join us in person or online via livestream.

In-person Location:

National Jewish Health - Molly Blank Conference Center
1400 Jackson Street
Denver, CO 80206

Campus map | Directions

Online registrants: The streaming link will be emailed to you the week of the event.

Lodging:

The Moxy Hotel is a preferred lodging partner for the conference. Secure discounted rooms by visiting www.Marriott.com/denox (Opens in a new window) then click the rates button and enter the promo code: JWP. Please visit the Hotels & Lodging in Denver page for information on hotels suggestions. For more information on traveling to Denver visit our Travel Page.

Thank you to our valued Sponsor and Exhibitors for supporting the 2026 NTM & Bronchiectasis Conference for Healthcare Providers and the NTM & Bronchiectasis Patient and Family Course. We encourage you to visit the Sponsors and Exhibitors in the exhibit hall during the scheduled exhibit times to connect and learn about their products and services.

Platinum Sponsor

Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan.

Exhibitors:

ABM Respiratory Care
Advanced Diagnostic Laboratories at National Jewish Health (Opens in a new window)
Baxter
Boehringer Ingelheim (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window)
NTMir (Opens in a new window) (Opens in a new window) (Opens in a new window)
(Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new windo (Opens in a new window) (Opens in a new window) (Opens in a new window) (Opens in a new window)RespirTech
Smartvest by Electromed, Inc

We'd additionally like to thank Insmed for sponsoring the welcome reception and a lunch during the NTM & Bronchiectasis Conference for Healthcare Providers as well lunch at the NTM & Bronchiectasis Patient and Family Course.

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and an educational grant from Insmed.

Accreditation & Designation* Statements

Physicians: National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Jewish Health designates this live activity for a maximum of 18.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nurses: Provider approved by the California Board of Registered Nursing, Provider Number 12724, for 18.5 contact hours.

*Credit hours are subject to change slightly dependent upon finalization of the agenda.

Support Statement

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and an educational grant from Insmed

Registration Fees

The following fees are for in-person and livestreaming options. In-person attendees receive meals and snacks daily. All options include post-event access to the recordings of the live sessions through March 31, 2027, as well as CME/CNE credit for sessions viewed.

In Person:

MDs, DOs - $625
NPs, PAs, RPhs, RNs and other Allied Health Professionals - $525

Online (Livestreamed):

MDs, DOs - $500
NPs, PAs, RPhs, RNs and other Allied Health Professionals - $400

Recordings and slides from this course will be available to all registered attendees through March 31, 2027 with credit claiming.

If you are having problems registering, or need to make payment arrangements, please call 303-398-1000 or 800-844-2305 or email ProEd@NJHealth.org.

Cancellations

Virtual registrations are non-refundable and non-transferable. In-person registration cancellations/changes must be received in writing before August 16, 2026 in order to be eligible for a full refund or transfer. For cancellations made on or following August 16, 2026, there are three options:

Transfer your paid registration to somebody else
Hold your paid registration until next year’s conference
Refund of registration amount paid minus a $100 processing fee

No refunds or credits will be given after September 9, 2026

Add to Calendar